Balmer Lawrie Investment Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: December 5, 2025, 5:00 am

Competitors of Balmer Lawrie Investment Ltd

All Competitor Stocks of Balmer Lawrie Investment Ltd

Quarterly Result

Last Updated: August 19, 2025, 10:45 pm

Below is a detailed analysis of the quarterly data for Balmer Lawrie Investment Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 683.00 Cr.. The value appears strong and on an upward trend. It has increased from 611.00 Cr. (Mar 2025) to 683.00 Cr., marking an increase of 72.00 Cr..
• For Expenses, as of Jun 2025, the value is 598.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 514.00 Cr. (Mar 2025) to 598.00 Cr., marking an increase of 84.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 86.00 Cr.. The value appears to be declining and may need further review. It has decreased from 97.00 Cr. (Mar 2025) to 86.00 Cr., marking a decrease of 11.00 Cr..
• For OPM %, as of Jun 2025, the value is 13.00%. The value appears to be declining and may need further review. It has decreased from 16.00% (Mar 2025) to 13.00%, marking a decrease of 3.00%.
• For Other Income, as of Jun 2025, the value is 25.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 25.00 Cr., marking a decrease of 8.00 Cr..
• For Interest, as of Jun 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 2.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 89.00 Cr.. The value appears to be declining and may need further review. It has decreased from 107.00 Cr. (Mar 2025) to 89.00 Cr., marking a decrease of 18.00 Cr..
• For Tax %, as of Jun 2025, the value is 22.00%. The value appears to be improving (decreasing) as expected. It has decreased from 30.00% (Mar 2025) to 22.00%, marking a decrease of 8.00%.
• For Net Profit, as of Jun 2025, the value is 69.00 Cr.. The value appears to be declining and may need further review. It has decreased from 75.00 Cr. (Mar 2025) to 69.00 Cr., marking a decrease of 6.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 2.01. The value appears to be declining and may need further review. It has decreased from 2.17 (Mar 2025) to 2.01, marking a decrease of 0.16.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 3:49 am

Growth

Last Updated: September 5, 2025, 2:36 pm

Balance Sheet

Last Updated: December 4, 2025, 2:29 am

Below is a detailed analysis of the balance sheet data for Balmer Lawrie Investment Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 22.00 Cr..
• For Reserves, as of Sep 2025, the value is 1,337.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,354.00 Cr. (Mar 2025) to 1,337.00 Cr., marking a decrease of 17.00 Cr..
• For Borrowings, as of Sep 2025, the value is 237.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 106.00 Cr. (Mar 2025) to 237.00 Cr., marking an increase of 131.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 1,797.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,723.00 Cr. (Mar 2025) to 1,797.00 Cr., marking an increase of 74.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 3,393.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,204.00 Cr. (Mar 2025) to 3,393.00 Cr., marking an increase of 189.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 789.00 Cr.. The value appears strong and on an upward trend. It has increased from 737.00 Cr. (Mar 2025) to 789.00 Cr., marking an increase of 52.00 Cr..
• For CWIP, as of Sep 2025, the value is 79.00 Cr.. The value appears strong and on an upward trend. It has increased from 67.00 Cr. (Mar 2025) to 79.00 Cr., marking an increase of 12.00 Cr..
• For Investments, as of Sep 2025, the value is 669.00 Cr.. The value appears strong and on an upward trend. It has increased from 632.00 Cr. (Mar 2025) to 669.00 Cr., marking an increase of 37.00 Cr..
• For Other Assets, as of Sep 2025, the value is 1,855.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,769.00 Cr. (Mar 2025) to 1,855.00 Cr., marking an increase of 86.00 Cr..
• For Total Assets, as of Sep 2025, the value is 3,393.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,204.00 Cr. (Mar 2025) to 3,393.00 Cr., marking an increase of 189.00 Cr..

Notably, the Reserves (1,337.00 Cr.) exceed the Borrowings (237.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Balmer Lawrie Investment Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 1.00, marking a decrease of 9.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 7.73. This value is within the healthy range. It has decreased from 75.68 (Mar 24) to 7.73, marking a decrease of 67.95.
• For Diluted EPS (Rs.), as of Mar 25, the value is 7.73. This value is within the healthy range. It has decreased from 75.68 (Mar 24) to 7.73, marking a decrease of 67.95.
• For Cash EPS (Rs.), as of Mar 25, the value is 11.82. This value is within the healthy range. It has decreased from 119.31 (Mar 24) to 11.82, marking a decrease of 107.49.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 61.98. It has decreased from 549.97 (Mar 24) to 61.98, marking a decrease of 487.99.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 61.98. It has decreased from 549.97 (Mar 24) to 61.98, marking a decrease of 487.99.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 113.81. It has decreased from 1,057.87 (Mar 24) to 113.81, marking a decrease of 944.06.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has decreased from 164.10 (Mar 24) to 16.78, marking a decrease of 147.32.
• For PBIT / Share (Rs.), as of Mar 25, the value is 14.06. This value is within the healthy range. It has decreased from 137.44 (Mar 24) to 14.06, marking a decrease of 123.38.
• For PBT / Share (Rs.), as of Mar 25, the value is 12.87. This value is within the healthy range. It has decreased from 127.51 (Mar 24) to 12.87, marking a decrease of 114.64.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 9.10. This value is within the healthy range. It has decreased from 92.65 (Mar 24) to 9.10, marking a decrease of 83.55.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.73. This value is within the healthy range. It has decreased from 75.68 (Mar 24) to 7.73, marking a decrease of 67.95.
• For PBDIT Margin (%), as of Mar 25, the value is 14.74. This value is within the healthy range. It has decreased from 15.51 (Mar 24) to 14.74, marking a decrease of 0.77.
• For PBIT Margin (%), as of Mar 25, the value is 12.35. This value is within the healthy range. It has decreased from 12.99 (Mar 24) to 12.35, marking a decrease of 0.64.
• For PBT Margin (%), as of Mar 25, the value is 11.30. This value is within the healthy range. It has decreased from 12.05 (Mar 24) to 11.30, marking a decrease of 0.75.
• For Net Profit Margin (%), as of Mar 25, the value is 7.99. This value is within the healthy range. It has decreased from 8.75 (Mar 24) to 7.99, marking a decrease of 0.76.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.79. This value is below the healthy minimum of 8. It has decreased from 7.15 (Mar 24) to 6.79, marking a decrease of 0.36.
• For Return on Networth / Equity (%), as of Mar 25, the value is 12.47. This value is below the healthy minimum of 15. It has decreased from 13.76 (Mar 24) to 12.47, marking a decrease of 1.29.
• For Return on Capital Employeed (%), as of Mar 25, the value is 12.47. This value is within the healthy range. It has decreased from 13.21 (Mar 24) to 12.47, marking a decrease of 0.74.
• For Return On Assets (%), as of Mar 25, the value is 5.36. This value is within the healthy range. It has decreased from 5.55 (Mar 24) to 5.36, marking a decrease of 0.19.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.05.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.05. This value is within the healthy range. It has decreased from 0.06 (Mar 24) to 0.05, marking a decrease of 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.81. It has increased from 0.80 (Mar 24) to 0.81, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 2.49. This value is within the healthy range. It has increased from 2.29 (Mar 24) to 2.49, marking an increase of 0.20.
• For Quick Ratio (X), as of Mar 25, the value is 2.22. This value exceeds the healthy maximum of 2. It has increased from 2.02 (Mar 24) to 2.22, marking an increase of 0.20.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 13.09. This value exceeds the healthy maximum of 8. It has increased from 11.79 (Mar 24) to 13.09, marking an increase of 1.30.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 49.14. This value is within the healthy range. It has increased from 43.60 (Mar 24) to 49.14, marking an increase of 5.54.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 36.37. This value is within the healthy range. It has increased from 32.24 (Mar 24) to 36.37, marking an increase of 4.13.
• For Earning Retention Ratio (%), as of Mar 25, the value is 50.86. This value is within the healthy range. It has decreased from 56.40 (Mar 24) to 50.86, marking a decrease of 5.54.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 63.63. This value is within the healthy range. It has decreased from 67.76 (Mar 24) to 63.63, marking a decrease of 4.13.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 14.04. This value is within the healthy range. It has decreased from 16.52 (Mar 24) to 14.04, marking a decrease of 2.48.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.62. This value is within the healthy range. It has decreased from 10.33 (Mar 24) to 8.62, marking a decrease of 1.71.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,724.29. It has increased from 1,534.20 (Mar 24) to 1,724.29, marking an increase of 190.09.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has increased from 0.65 (Mar 24) to 0.68, marking an increase of 0.03.
• For EV / EBITDA (X), as of Mar 25, the value is 4.63. This value is below the healthy minimum of 5. It has increased from 4.21 (Mar 24) to 4.63, marking an increase of 0.42.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has increased from 0.57 (Mar 24) to 0.59, marking an increase of 0.02.
• For Retention Ratios (%), as of Mar 25, the value is 50.85. This value is within the healthy range. It has decreased from 56.39 (Mar 24) to 50.85, marking a decrease of 5.54.
• For Price / BV (X), as of Mar 25, the value is 1.09. This value is within the healthy range. It has decreased from 1.11 (Mar 24) to 1.09, marking a decrease of 0.02.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has increased from 0.57 (Mar 24) to 0.59, marking an increase of 0.02.
• For EarningsYield, as of Mar 25, the value is 0.11. This value is below the healthy minimum of 5. It has decreased from 0.12 (Mar 24) to 0.11, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness